Who are ERA as specific PAH treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tryvio, SPARSENTAN, Opsumit, Letairis, Tracleer, Ambrisentan plus Spironolactone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/era-as-specific-pah-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ERA as specific PAH treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ERA as specific PAH treatment (ERA as specific PAH treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin receptor antagonist. Area: Cardiovascular.

phase 3 Endothelin receptor antagonist Endothelin receptor (ETA/ETB) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ERA as specific PAH treatment (ERA as specific PAH treatment) — Eli Lilly and Company. Endothelin receptor antagonists (ERAs) block endothelin-1 signaling in pulmonary vasculature to reduce vasoconstriction and improve hemodynamics in pulmonary arterial hypertension.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ERA as specific PAH treatment TARGET	ERA as specific PAH treatment	Eli Lilly and Company	phase 3	Endothelin receptor antagonist	Endothelin receptor (ETA/ETB)
Tryvio	APROCITENTAN	Idorsia	marketed	Endothelin Receptor Antagonist [EPC]		2025-01-01
SPARSENTAN	SPARSENTAN		marketed	Endothelin Receptor Antagonist [EPC]		2023-01-01
Opsumit	MACITENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2013-01-01
Letairis	AMBRISENTAN	Gilead Sciences	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2007-01-01
Tracleer	BOSENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist	Endothelin-1 receptor	2001-01-01
Ambrisentan plus Spironolactone	Ambrisentan plus Spironolactone	Brigham and Women's Hospital	marketed	Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination	Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor

Recent regulatory actions (last 90 days)

2026-03-03 — Tracleer · FDA · approved · US · AstraZeneca

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-12-28 — Tracleer · 7959945 · Formulation · US

Sponsor landscape (Endothelin receptor antagonist class)

AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Actelion · 2 drugs in this class
Bayer · 1 drug in this class
Dr Sudarshan Rajagopal · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Elpen Pharmaceutical Co. Inc. · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ERA as specific PAH treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/era-as-specific-pah-treatment. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab